Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. OFIX
OFIX logo

OFIX Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
11.750
Open
11.680
VWAP
11.56
Vol
240.20K
Mkt Cap
461.66M
Low
11.420
Amount
2.78M
EV/EBITDA(TTM)
11.78
Total Shares
40.14M
EV
554.92M
EV/OCF(TTM)
16.64
P/S(TTM)
0.55
Orthofix Medical Inc. is a global medical technology company. The Company offers a portfolio of spinal hardware, bone growth therapies, specialized orthopedic solutions, biologics and enabling technologies, including the 7D FLASH navigation system. The Company’s Global Spine segment offers two primary product categories: bone growth therapies and spinal implants, biologics, and enabling technologies. The segment provides implantable medical devices, biologics, enabling technologies, and other regenerative solutions which aim to restore the quality of life of patients suffering from diseases and traumas of the spine. It offers a variety of treatment solutions that incorporate multiple treatment modalities, such as mechanical, biological, and electromagnetic modes. Its Global Orthopedics segment offers products and solutions for limb deformity correction and complex limb reconstruction with a focus on use in trauma, adult and pediatric limb reconstruction, and foot and ankle procedures.
Show More

Events Timeline

(ET)
2026-02-24
07:40:00
Company Expects FY26 Adjusted EBITDA of $95M-$98M
select
2026-02-24
07:30:00
Orthofix Reports Q4 Revenue of $219.91M, Beating Consensus
select
2025-11-04 (ET)
2025-11-04
07:32:20
Orthofix Revises FY25 Revenue Forecast to $810M-$814M, Down from $808M-$816M
select
2025-11-04
07:30:24
Orthofix Announces Q3 Earnings Per Share of 57 Cents, Compared to 71 Cents Last Year
select

News

seekingalpha
9.5
02-24seekingalpha
Orthofix Medical Inc. Reports Strong Q4 2025 Earnings with Positive Outlook
  • Significant Sales Growth: Orthofix Medical Inc. reported global net sales of $218.6 million in Q4, reflecting a 3% year-over-year increase, driven by strong performances in Bone Growth Therapies and U.S. Limb Reconstruction, showcasing the company's competitive edge and growth potential in the market.
  • Consistent EBITDA Growth: The company achieved its eighth consecutive quarter of adjusted EBITDA growth, with Q4 EBITDA reaching $29.2 million, or 13.4% of net sales, marking a year-over-year margin expansion of approximately 230 basis points, indicating improved operational efficiency.
  • Optimistic Future Outlook: Management guided full-year 2026 net sales to be between $850 million and $860 million, representing an implied year-over-year growth of about 5.5%, and aims for a long-term sales CAGR of 6.5% to 7.5% from 2026 to 2028 through product launches and channel optimization.
  • Strong Free Cash Flow: The company generated $16.8 million in free cash flow for Q4 and $3.1 million for the full year, demonstrating the strength and scalability of its business model, providing ample funding for future investments and growth.
seekingalpha
9.5
02-24seekingalpha
Orthofix Medical Inc. Q4 Earnings Beat Expectations
  • Earnings Highlights: Orthofix Medical Inc. reported a Q4 GAAP EPS of -$0.06, beating expectations by $0.13, with revenue of $219.91 million reflecting a 2% year-over-year growth, indicating stable market performance.
  • Non-GAAP Metrics: The company achieved non-GAAP pro forma net sales of $218.6 million in Q4, excluding M6 disc sales, which represents a 3% increase on a constant currency basis, showcasing ongoing growth potential in its core business.
  • Cash Flow Performance: Orthofix generated robust free cash flow of $16.8 million in Q4, reflecting improved operational efficiency and financial health, thereby enhancing its capacity for future investments.
  • 2026 Outlook: The company projects net sales for 2026 to range between $850 million and $860 million, slightly below the consensus of $862.76 million, yet indicating a potential year-over-year growth of approximately 5.5%, demonstrating confidence in future market conditions.
seekingalpha
9.5
02-23seekingalpha
Orthofix Medical Inc. Set to Release Q4 Earnings on February 24
  • Earnings Announcement: Orthofix Medical Inc. is scheduled to announce its Q4 earnings on February 24 before market open, with investors keenly awaiting the results to assess future growth potential.
  • Earnings Expectations: The consensus EPS estimate stands at $0.41, reflecting a substantial year-over-year increase of 154.7%, indicating a significant improvement in profitability that may attract more investor interest.
  • Revenue Projections: The consensus revenue estimate is $218.71 million, representing a modest year-over-year growth of 1.4%, which, while small, still indicates stable performance in the market, potentially bolstering investor confidence.
  • Historical Performance Review: Over the past year, Orthofix has beaten EPS estimates 50% of the time and revenue estimates 75% of the time, demonstrating consistency and reliability in financial performance, which could positively impact its stock price.
Yahoo Finance
2.0
02-21Yahoo Finance
Overview of 13D Filings
  • Definition of 13D Filings: 13D filings are disclosures required to be submitted to the SEC within 10 days when an entity acquires more than 5% of any class of a company's securities, aimed at enhancing market transparency.
  • Purpose of Disclosure: The primary purpose of these filings is to inform investors about the holdings of major shareholders and their potential impact on corporate governance and strategic decisions, thereby aiding market participants in making more informed investment choices.
  • Compliance Requirements: Under U.S. securities law, any investor holding more than 5% must timely submit a 13D filing to ensure that all market participants have access to relevant information, thus maintaining market fairness.
  • Market Impact: The disclosure of 13D filings can trigger market interest in the related companies, influencing their stock price volatility, especially when investors speculate on the intentions and future plans of major shareholders.
NASDAQ.COM
2.0
01-28NASDAQ.COM
Healthcare Stocks Surge in After-Hours Trading
  • Acumen Pharmaceuticals Surge: Acumen Pharmaceuticals, Inc. (ABOS) advanced 8.09% in after-hours trading to close at $2.94, adding $0.22, indicating strong investor confidence in its growth prospects.
  • Fulgent Genetics Rise: Fulgent Genetics, Inc. (FLGT) rose 5.98% to $28.90 in after-hours trading, gaining $1.63, reflecting market optimism regarding its business outlook.
  • Fractyl Health Growth: Fractyl Health, Inc. (GUTS) climbed 5.19% to $2.23 after hours, up $0.11, suggesting that its potential in the biotech sector is being recognized by the market.
  • Coeptis Therapeutics Increase: Coeptis Therapeutics Holdings, Inc. (COEP) added 4.14% to finish at $13.85, gaining $0.55 in after-hours trading, demonstrating investor support for its strategic direction.
Globenewswire
2.0
01-16Globenewswire
Bone Grafts Market Report: Forecast to 2036
  • Market Size Forecast: The report indicates significant growth in the bone grafts and substitutes market projected by 2036, with detailed intervention volumes and market value data across 39 countries aiding strategic decision-making for businesses.
  • Product Segmentation Analysis: It provides an in-depth analysis of various bone graft substitutes, including allograft bone chips and bone morphogenetic proteins, offering insights into market share and average selling prices to help companies optimize their product portfolios.
  • Competitive Dynamics Insights: Through SWOT analysis and exploration of competitive dynamics, the report reveals the market positions of key players such as Medtronic and Stryker, assisting investors in identifying potential investment opportunities.
  • Market Access Strategies: Additionally, the report offers detailed information on market access, including reimbursement policies and regulatory landscapes, enabling companies to formulate effective market entry strategies in a complex environment.
Wall Street analysts forecast OFIX stock price to rise
3 Analyst Rating
Wall Street analysts forecast OFIX stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
18.00
Averages
21.33
High
24.00
Current: 0.000
sliders
Low
18.00
Averages
21.33
High
24.00
Stifel
Buy -> Buy
downgrade
$22 -> $18
AI Analysis
2026-03-09
Reason
Stifel
Price Target
$22 -> $18
AI Analysis
2026-03-09
downgrade
Buy -> Buy
Reason
Stifel lowered the firm's price target on Orthofix to $18 from $22 and keeps a Buy rating on the shares. The firm updated models across its medical technology and supplies coverage following Q4 reporting from the group.
Canaccord
Buy
downgrade
$24 -> $20
2026-02-26
Reason
Canaccord
Price Target
$24 -> $20
2026-02-26
downgrade
Buy
Reason
Canaccord lowered the firm's price target on Orthofix to $20 from $24 and keeps a Buy rating on the shares. The firm updated its model to reflect Q4 results and 2026 guidance.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for OFIX
Unlock Now

Valuation Metrics

The current forward P/E ratio for Orthofix Medical Inc (OFIX.O) is -8.78, compared to its 5-year average forward P/E of -16.26. For a more detailed relative valuation and DCF analysis to assess Orthofix Medical Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-16.26
Current PE
-8.78
Overvalued PE
86.65
Undervalued PE
-119.16

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
9.68
Current EV/EBITDA
7.76
Overvalued EV/EBITDA
12.47
Undervalued EV/EBITDA
6.88

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.93
Current PS
0.69
Overvalued PS
1.30
Undervalued PS
0.56

Financials

AI Analysis
Annual
Quarterly

Whales Holding OFIX

P
Paradigm Capital Management, Inc.
Holding
OFIX
+11.66%
3M Return
R
Rubric Capital Management LP
Holding
OFIX
+1.39%
3M Return
A
Armistice Capital LLC
Holding
OFIX
-9.60%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Orthofix Medical Inc (OFIX) stock price today?

The current price of OFIX is 11.5 USD — it has decreased -2.46

What is Orthofix Medical Inc (OFIX)'s business?

Orthofix Medical Inc. is a global medical technology company. The Company offers a portfolio of spinal hardware, bone growth therapies, specialized orthopedic solutions, biologics and enabling technologies, including the 7D FLASH navigation system. The Company’s Global Spine segment offers two primary product categories: bone growth therapies and spinal implants, biologics, and enabling technologies. The segment provides implantable medical devices, biologics, enabling technologies, and other regenerative solutions which aim to restore the quality of life of patients suffering from diseases and traumas of the spine. It offers a variety of treatment solutions that incorporate multiple treatment modalities, such as mechanical, biological, and electromagnetic modes. Its Global Orthopedics segment offers products and solutions for limb deformity correction and complex limb reconstruction with a focus on use in trauma, adult and pediatric limb reconstruction, and foot and ankle procedures.

What is the price predicton of OFIX Stock?

Wall Street analysts forecast OFIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OFIX is21.33 USD with a low forecast of 18.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Orthofix Medical Inc (OFIX)'s revenue for the last quarter?

Orthofix Medical Inc revenue for the last quarter amounts to 219.91M USD, increased 1.97

What is Orthofix Medical Inc (OFIX)'s earnings per share (EPS) for the last quarter?

Orthofix Medical Inc. EPS for the last quarter amounts to -0.06 USD, decreased -92.00

How many employees does Orthofix Medical Inc (OFIX). have?

Orthofix Medical Inc (OFIX) has 1605 emplpoyees as of March 30 2026.

What is Orthofix Medical Inc (OFIX) market cap?

Today OFIX has the market capitalization of 461.66M USD.